Clinical Trial Goal
To find out if the combination of bortezomib and mezigdomide is safe and works well to treat multiple myeloma that has relapsed or is refractory compared to bortezomib and pomalidomide
You may be able to join this trial if you:
- Are 18 years or older
- Have multiple myeloma that has relapsed or is refractory
- Have not been treated with the following:
- Mezigdomide
- Pomalidomide
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Bortezomib is a small molecule inhibitor that blocks proteasome function in certain cells.
Mezigdomide is a drug that blocks the growth of cancer cells, similar to the drug lenalidomide. Doctors think it might work better at finding and killing myeloma cells.
Pomalidomide is a drug that blocks the growth of cancer cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
Mezigdomide is a drug that blocks the growth of cancer cells, similar to the drug lenalidomide. Doctors think it might work better at finding and killing myeloma cells.
Pomalidomide is a drug that blocks the growth of cancer cells.
In this trial, you’ll be randomized to 1 of 2 groups. Once you’re randomized, you’ll be told what group you’re in:
- Group 1 – Bortezomib, mezigdomide and dexamethasone
- Group 2 – Bortezomib, dexamethasone and pomalidomide
Randomized means doctors will use a computer to assign you to either group. A computer assigns you by chance, like flipping a coin or drawing a name out of a hat. You, your doctor or the clinical trial doctor won’t have any control over which group you’ll be assigned. This means you won’t be able to choose your group.
You’ll get:
- Bortezomib – Given as shots under your skin. The dose you'll get depends on when you start the trial and how safe it has been
- Mezigdomide – Group 1 only - A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Dexamethasone – Given as intravenous (IV) infusions or as a pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
- Pomalidomide – Group 2 only - A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has not yet approved mezigdomide.
Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com, 855-907-3286, Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
Locations
Sponsors
lead: Celgene
